Precision BioSciences, Inc. (DTIL)

Market Cap	131.04M
Revenue (ttm)	20.84M
Net Income (ttm)	-105.44M
Shares Out	110.96M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	162,139
Open	1.21
Previous Close	1.17
Day's Range	1.19 - 1.22
52-Week Range	0.95 - 5.20
Beta	1.47
Analysts	Buy
Price Target	6.46 (+442.86%)
Earnings Date	Mar 21, 2023

About DTIL

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblast...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 28, 2019
• Employees: 194
• Stock Exchange: NASDAQ
• Ticker Symbol: DTIL

Financial Performance

In 2021, DTIL's revenue was $115.53 million, an increase of 375.72% compared to the previous year's $24.29 million. Losses were -$30.60 million, -71.93% less than in 2020.

Analyst Forecast

According to 16 analysts, the average rating for DTIL stock is "Buy." The 12-month stock price forecast is $6.46, which is an increase of 442.86% from the latest price.

Price Target

$6.46

(442.86% upside)

Analyst Consensus: Buy